A major factor in the respiratory health of Cystic Fibrosis (CF) subjects is the prevalence
of chronic Pseudomonas aeruginosa (Pa) infections. The Pa infection rate in CF patients
increases with age and by age 18 years approximately 85% of CF patients in the US are
infected. Liposomal amikacin for inhalation (Arikayce™) was developed as a possible treatment
for chronic infection due to Pa in CF patients.
The purpose of this study is to determine whether Arikayce™ is effective in treating chronic
lung infections caused by Pa in CF subjects. The effectiveness, safety, and tolerability of
Arikayce™ will be compared to Tobramycin TOBI®, an inhalation antibiotic already available